Levodopa-induced pseudopheochromocytoma

  • Joana Bernardino Cardoso Centro Hospitalar e Universitário de Coimbra
  • Ana Silveira Hospital da Horta, Azores, Portugal
  • Sara Duarte Hospital da Horta, Azores, Portugal
  • Ruth Fortes Hospital da Horta, Azores, Portugal
  • Ahmed Botelho Hospital da Horta, Azores, Portugal
  • Ana Simas Hospital da Horta, Azores, Portugal
  • Rui Suzano Hospital da Horta, Azores, Portugal


Pseudopheochromocytoma, paroxysmal hypertension, levodopa, Parkinson’s disease


Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
We describe a case of pseudopheochromocytoma related to levodopa in a patient with paroxysmal hypertension, headache, sweating, palpitations and increased plasmatic and urinary metanephrine levels, without adrenal or extra-adrenal tumour. The beginning of the patient´s clinical symptoms coincided with the initiation of the levodopa treatment and the complete resolution of the symptoms occurred after the discontinuation of levodopa.



  • Mamilla D, Gonzales MK, Esler MD, Pacak K. Pseudopheochromocytoma. Endocrinol Metab Clin North Am 2019;48:751–764.
  • Yeterian EH, Pandya DN. Corticothalamic connections of the superior temporal sulcus in rhesus monkeys. Exp Brain Res 1991;83:268–-284.
  • Parikh PP, Rubio GA, Farra JC, Lew JI. Nationwide review of hormonally active adrenal tumors highlights high morbidity in pheochromocytoma. J Surg Res 2017;215:204–210.
  • Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF, et al. Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens 2007;25:2286–2295.
  • Cailleux N, Marie I, Noblet C, Moore ND, Verdure L, Lévesque H, et al. Amoxapine-induced pseudopheochromocytoma. Apropos of a case. Rev Méd Interne 1998;19:139–141.
  • Davidson DF, Grosset K, Grosset D. Parkinson’s disease: the effect of l-dopa therapy on urinary free catecholamines and metabolites. Ann Clin Biochem 2007;44:364–368.
  • Ito D, Amano T, Sato H, Fukuuchi Y. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson’s disease. J Neurol 2001;248:533–534.
  • Rampton DS. Hypertensive crisis in a patient given sinemet, metoclopramide, and amitriptyline. Br Med J 1977;2:607–608.
  • Humbert X, Fedrizzi S, Chrétien B, Sassier M, Bagheri H, Combret S, et al. Hypertension induced by serotonin reuptake inhibitors: analysis of two pharmacovigilance databases. Fundam Clin Pharmacol 2019;33:296–302.
  • Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
  • Published: 2023-05-30

    Issue: 2023: Vol 10 No 6 (view)

    Section: Articles

    How to cite:
    Cardoso JB, Silveira A, Duarte S, Fortes R, Botelho A, Simas A, Suzano R. Levodopa-induced pseudopheochromocytoma. EJCRIM 2023;10 doi:10.12890/2023_003813.

    Most read articles by the same author(s)